<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00141024</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 064</org_study_id>
    <secondary_id>10059</secondary_id>
    <nct_id>NCT00141024</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Protein Vaccine EP-1043 and the DNA Vaccine EP HIV-1090 Given Alone or in Combination in Healthy, HIV-1-Uninfected Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety of and immune response to the&#xD;
      investigational HIV vaccine, EP HIV-1090, in HIV uninfected adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The worldwide HIV/AIDS epidemic may only be controlled through the development of a safe and&#xD;
      effective vaccine that will prevent HIV infection. DNA vaccines are inexpensive to construct,&#xD;
      readily produced in large quantities, and stable for long periods of time. EP HIV-1090 is a&#xD;
      DNA HIV CTL vaccine; the proteins for which its genes code are designed to interact with CD8&#xD;
      cells (CTL) and cause CD8 cell proliferation. The DNA plasmids in EP HIV-1090 code for&#xD;
      proteins conserved among HIV subtypes A, B, C, D, F, and G, which encompass the HLA subtypes&#xD;
      of 85% of the worldwide general population.&#xD;
&#xD;
      Participants will be enrolled in this study for 1 year. Group 4 participants will receive EP&#xD;
      HIV-1090 or placebo at study entry and Months 1, 3, and 6. There will be 11 study visits that&#xD;
      will occur at screening; study entry; and Months 0.5, 1, 1.5, 3, 3.5, 6, 6.5, 9, and 12. A&#xD;
      physical exam and risk reduction/pregnancy prevention counseling will occur at each visit.&#xD;
      Participants will be asked about their adverse experiences from vaccination at each visit.&#xD;
      Blood and urine collection will occur at selected visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by local and systemic reactogenicity signs and symptoms, laboratory measures, and adverse and serious experiences</measure>
    <time_frame>After each injection and for 12 months following the first injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as assessed by HIV-specific cellular responses assessed by interferon-gamma ELISpot assays and intracellular cytokine staining</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social impacts as assessed by negative experiences or problems reported by the participants</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, Group 3 will receive 4 vaccinations of either the EP-1043 vaccine or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, Group 4 will receive 4 vaccinations of either the DNA vaccine EP-HIV-1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, Group 5 will receive 4 vaccinations of either the protein vaccine EP-1043 plus DNA vaccine EP-HIV- 1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EP HIV-1043</intervention_name>
    <description>Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.&#xD;
The vaccine is provided in single-use 1.1-mL vials.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EP HIV-1090</intervention_name>
    <description>DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Note: Groups 1, 2, 3, and 5 have permanently discontinued enrollment per the 12/26/06&#xD;
        letter of amendment.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
          -  Have access to a participating HIV Vaccine Trials Unit (HVTU) and are willing to be&#xD;
             followed for the duration of the study&#xD;
&#xD;
          -  Willing to receive HIV test results&#xD;
&#xD;
          -  Have understanding of the study&#xD;
&#xD;
          -  Willing to use acceptable forms of contraception&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV vaccines in a prior HIV vaccine trial&#xD;
&#xD;
          -  Immunosuppressive medications within 168 days prior to first vaccination&#xD;
&#xD;
          -  Blood products within 120 days prior to first vaccination&#xD;
&#xD;
          -  Immunoglobulin within 60 days prior to first vaccination&#xD;
&#xD;
          -  Live attenuated vaccines within 30 days prior to first vaccination&#xD;
&#xD;
          -  Investigational research agents within 30 days prior to first vaccination&#xD;
&#xD;
          -  Medically indicated subunit or killed vaccines within 14 days prior to first study&#xD;
             vaccine administration, or allergy treatment with antigen injections within 30 days&#xD;
             prior to first vaccination&#xD;
&#xD;
          -  Current tuberculosis prophylaxis or therapy&#xD;
&#xD;
          -  Clinically significant medical condition, abnormal physical exam findings, abnormal&#xD;
             laboratory results, or past medical history that may affect current health&#xD;
&#xD;
          -  Any medical, psychiatric, or social condition that would interfere with the study.&#xD;
             More information about this criterion can be found in the protocol.&#xD;
&#xD;
          -  Any job-related responsibility that would interfere with the study&#xD;
&#xD;
          -  Serious adverse reaction to vaccines. A person who had an adverse reaction to&#xD;
             pertussis vaccine as a child is not excluded.&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Active syphilis infection unless the participant has completed full treatment for&#xD;
             syphilis 6 months prior to enrollment&#xD;
&#xD;
          -  Unstable asthma&#xD;
&#xD;
          -  Diabetes mellitus type 1 or 2&#xD;
&#xD;
          -  Thyroid disease or thyroidectomy requiring treatment&#xD;
&#xD;
          -  Serious angioedema within 3 years prior to enrollment&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Body mass index (BMI) of 40 or greater&#xD;
&#xD;
          -  BMI of 35 or greater if the participant is older than 45 years, has systolic blood&#xD;
             pressure greater than 140 mm Hg, has diastolic blood pressure greater than 90 mm Hg,&#xD;
             smokes, or has known hyperlipidemia&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Malignancy unless it has been surgically removed and, in the opinion of the&#xD;
             investigator, is not likely to recur during the study period&#xD;
&#xD;
          -  Seizure disorder requiring medication within the 3 years prior to enrollment&#xD;
&#xD;
          -  Absence of the spleen&#xD;
&#xD;
          -  Mental illness that would interfere with the study&#xD;
&#xD;
          -  Other conditions that, in the judgment of the investigator, would interfere with the&#xD;
             study&#xD;
&#xD;
          -  Pregnancy, breastfeeding, or plans to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia Jin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Sanchez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación Civil Impacta Salud y Educación (IMPACTA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Vaccine and Prevention CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102-6033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Project Brave HIV Vaccine CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester HVTN CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVPreventionVaccines_FS_en.pdf</url>
    <description>Click here for more information about preventive HIV vaccines</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1566</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr Mol Med. 2003 May;3(3):183-93. Review.</citation>
    <PMID>12699356</PMID>
  </reference>
  <reference>
    <citation>Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection. Science. 2002 Jun 28;296(5577):2354-60. Review.</citation>
    <PMID>12089434</PMID>
  </reference>
  <reference>
    <citation>Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine. 2001 Sep 14;19(32):4652-60.</citation>
    <PMID>11535313</PMID>
  </reference>
  <reference>
    <citation>McKinney DM, Skvoretz R, Livingston BD, Wilson CC, Anders M, Chesnut RW, Sette A, Essex M, Novitsky V, Newman MJ. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol. 2004 Aug 1;173(3):1941-50.</citation>
    <PMID>15265928</PMID>
  </reference>
  <reference>
    <citation>Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, Livingston BD. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol. 2003 Nov 15;171(10):5611-23.</citation>
    <PMID>14607970</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

